Unidade Local De Saude De Entre O Douro E Vouga E.P.E.

The trials here

What the 31 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis6 trials
• Epilepsy5 trials
• Atrial fibrillation3 trials
• Crohn's disease3 trials
• Heart failure3 trials
• Obesity3 trials
• Ulcerative colitis3 trials
• Chronic rhinosinusitis with nasal polyps2 trials
• Stroke2 trials
• Chronic kidney disease1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• and 4 more

Phase

• Phase 324 trials
• Phase 23 trials
• Phase 2/33 trials
• Phase 11 trial

Status

• Active, not recruiting10 trials
• Recruiting9 trials
• Completed7 trials
• Not yet recruiting5 trials

Lead sponsor

• Hoffmann-La Roche7 trials
• Amgen Inc.3 trials
• Biohaven Therapeutics Ltd.3 trials
• Janssen Research & Development, LLC3 trials
• Sanofi3 trials
• and 9 more

Running trials

• Not yet recruiting

  A study to compare heart failure medicines in one combined pill with usual care.

  2026-526510-90-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

  2025-524404-29-00· Phase 2· Eli Lilly & Co.· Source

• Recruiting

  Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

  NCT07563881· Phase 3· Rapport Therapeutics Inc.· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

  NCT07430956· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

  NCT06834347· Phase 3· Sanofi· Source

• Recruiting

  Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

  2022-502352-31-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

  NCT05704361· Phase 1· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

  NCT04586010· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis3 recruiting
• Atrial fibrillation2 recruiting
• Crohn's disease2 recruiting
• Epilepsy2 recruiting
• Heart failure2 recruiting
• Stroke2 recruiting
• Colorectal cancer1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Active, not recruiting

  An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

  NCT07424144· Phase 3· Sanofi· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source